Radiation and anti-PD-L1 antibody combinatorial therapy induces T cell-mediated depletion of myeloid-derived suppressor cells and tumor regression

Liufu Deng, Hua Liang, Byron Burnette, Ralph R. Weichselbaum, Yang Xin Fu

Research output: Contribution to journalArticle

37 Scopus citations

Abstract

Tumor relapse after radiotherapy may be due to the upregulation of programmed cell death ligand 1 (PD-L1). We demonstrated that anti-PD-L1 antibody synergizes with radiation to control local and distal tumors. CD8+T cells mediated antitumor effects of the combination therapy by the reduction of myeloid-derived suppressor cells (MDSCs) via tumor-necrosis factor (TNF)-mediated signaling. Our study provides insight into immune- and radiation-based combinational therapies.

Original languageEnglish (US)
Article numbere28499
JournalOncoImmunology
Volume3
Issue number4
DOIs
StatePublished - Jan 1 2014

Keywords

  • Antibody therapy
  • Myeloid-derived suppressor cell
  • Negative signal
  • PD-L1
  • Radiation therapy
  • T-cell activation
  • TNF

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Fingerprint Dive into the research topics of 'Radiation and anti-PD-L1 antibody combinatorial therapy induces T cell-mediated depletion of myeloid-derived suppressor cells and tumor regression'. Together they form a unique fingerprint.

  • Cite this